isoxazoles has been researched along with Nerve Degeneration in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bayram, E; Karaoğlu, P; Kumral, A; Kurul, SH; Ozbal, S; Topçu, Y; Tuğyan, K; Yılmaz, O; Yiş, U | 1 |
| Murata, M; Nambu, A; Sano, H | 1 |
| Fernández-Ruiz, J; García-Arencibia, M; García-Toscano, L; Gómez-Cañas, M; Jagerovic, N; Morales, P; Muñoz, E; Navarrete, C; Pazos, MR | 1 |
| Araki, T; Kasahara, J; Kato, H; Kuroiwa, H; Tsukada, T; Uchida, H; Yano, R; Yokoyama, H | 2 |
| Allen, CN; Lambein, F; Ludolph, AC; Riepe, M; Spencer, PS | 1 |
| Diemer, NH; Johansen, FF | 1 |
7 other study(ies) available for isoxazoles and Nerve Degeneration
| Article | Year |
|---|---|
Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Disease Models, Animal; Hyperoxia; Immunohistochemistry; In Situ Nick-End Labeling; Isoxazoles; Nerve Degeneration; Neuroprotective Agents; Rats; Rats, Wistar; Zonisamide | 2014 |
Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Dopaminergic Neurons; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Zonisamide | 2015 |
Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
Topics: Animals; Binding Sites; Blood-Brain Barrier; Brain; Brain Injuries; Cannabinoid Receptor Agonists; Cell Line; Disease Models, Animal; Humans; Isoxazoles; Male; Malonates; Mice; Models, Biological; Nerve Degeneration; Neurons; Neuroprotective Agents; Permeability; Protein Binding; Rats, Wistar; Receptor, Cannabinoid, CB2; Transfection | 2016 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide | 2010 |
Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Dopamine; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Treatment Outcome; Zonisamide | 2010 |
In vitro toxicological investigations of isoxazolinone amino acids of Lathyrus sativus.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Alanine; Aminobutyrates; Animals; Electrophysiology; Hippocampus; Isoxazoles; Lathyrism; Mice; Motor Cortex; Nerve Degeneration; Plants, Toxic | 1995 |
Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal CA1 pyramidal cells.
Topics: Animals; Arousal; Brain Ischemia; Cell Count; Cell Survival; Diazepam; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Hippocampus; Isoxazoles; Male; Motor Activity; Nerve Degeneration; Neurons; Nipecotic Acids; Rats; Rats, Inbred Strains; Synaptic Transmission; Tiagabine | 1991 |